Open AccessPregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine
Author(s) -
Hongfei Zhang,
Jaime Bastian,
Wenchen Zhao,
Huijun Chen,
Imam H. Shaik,
Nupur Chaphekar,
Steve N. Caritis,
Raman Venkataramanan
Publication year - 2020
Publication title -
therapeutic drug monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 93
eISSN - 1536-3694
pISSN - 0163-4356
DOI - 10.1097/ftd.0000000000000724
Subject(s) - pregnancy , medicine , buprenorphine , dosing , pharmacokinetics , methadone , opioid , postpartum period , pharmacology , opioid use disorder , gestation , prospective cohort study , obstetrics , anesthesia , genetics , receptor , biology
In the United States, drug addiction has become a nationwide health crisis. Recently, buprenorphine (BUP), a maintenance therapy approved by the Food and Drug Administration, has been increasingly used in pregnant women for the treatment of opioid use disorder. Pregnancy is associated with various anatomic and physiological changes, which may result in altered drug pharmacokinetics (PKs). Previously, we reported that dose-adjusted plasma concentrations of BUP are lower during pregnancy than after pregnancy. The mechanism(s) responsible for this difference has not yet been defined. Our study aimed to evaluate alterations in cytochromes P450 (CYP)- and uridine diphosphate glucunosyltransferases (UGT)-mediated metabolism of BUP during pregnancy to determine the mechanism(s) responsible for this observation.